Overview

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The main objective of this interdisciplinary study is to develop an understanding of the molecular imaging features of blast-related mild traumatic brain injury (mTBI) in military personnel, while helping to establish assessment tools that may be of use in diagnosis, determining prognosis, and in future therapeutic clinical trials. Additionally, the objective is to evaluate feasibility of [18F]PI-2620 in the assessment TBI.
Phase:
Phase 1
Details
Lead Sponsor:
Life Molecular Imaging SA
Collaborator:
Walter Reed National Military Medical Center